2/9
09:20 am
nrsn
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
Low
Report
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
1/21
08:30 am
nrsn
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
Medium
Report
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
1/8
09:23 am
nrsn
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB [Yahoo! Finance]
Medium
Report
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB [Yahoo! Finance]
1/8
08:45 am
nrsn
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Medium
Report
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
1/3
01:08 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at
Wall S
High
Report
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at
Wall S
12/22
11:14 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
12/22
10:01 am
nrsn
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study [Yahoo! Finance]
Medium
Report
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study [Yahoo! Finance]
12/22
09:17 am
nrsn
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
Medium
Report
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
12/13
01:10 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by analysts at
Wall
Medium
Report
NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by analysts at
Wall
12/4
07:30 am
nrsn
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
Medium
Report
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
11/24
11:04 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
11/24
09:56 am
nrsn
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
Medium
Report
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS